Related Experiment Video
Updated: Jun 3, 2026
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
When should prophylaxis therapy in inhibitor patients be considered?
G Young1, G Auerswald, V Jimenez-Yuste
1Children's Hospital Los Angeles, University of Southern California Keck School of Medicine, Los Angeles, CA, USA. gyoung@chla.usc.edu
Summary
Prophylaxis with bypassing agents may be effective and safe for severe hemophilia patients with inhibitors, preventing joint bleeds and arthropathy. This approach offers a new therapeutic option for managing this challenging complication.
Area of Science:
- Hematology
- Internal Medicine
- Pharmacology
Background:
- Severe hemophilia patients often develop neutralizing antibodies (inhibitors) to factor replacement therapy.
- Inhibitors render standard hemophilia treatment ineffective, leading to recurrent joint bleeding and arthropathy.
- Prophylactic therapy was previously not considered for inhibitor patients due to a lack of effective agents.
Purpose of the Study:
- To review current data on the efficacy and safety of bypassing agents for prophylaxis in hemophilia patients with inhibitors.
- To identify specific clinical situations where prophylaxis with bypassing agents could be considered for these patients.
Main Methods:
- Review of accumulated case reports on bypassing agent prophylaxis.
- Analysis of a recent prospective study evaluating bypassing agent prophylaxis.
- Synthesis of current data to inform clinical considerations.
Main Results:
- Emerging data suggest that prophylaxis with available bypassing agents can be effective in selected patients with inhibitors.
- Current evidence indicates that this prophylactic approach appears to be safe in specific cases.
- Accumulated reports and a prospective study support the potential benefits of this strategy.
Conclusions:
- Prophylaxis with bypassing agents represents a potential therapeutic advancement for hemophilia patients with inhibitors.
- Careful patient selection is crucial for the successful implementation of this prophylactic strategy.
- Further research and clinical experience are warranted to optimize the use of bypassing agents in this population.
Related Concept Videos
01:30Inhibitors of Viral Protein Synthesis
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
01:14Myocarditis III: Medical Management
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
01:28Pulmonary Tuberculosis V
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:25Pharmacokinetics: Drug–Drug Interactions
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...